Cyramza ® (ramucirumab) injection

10 mg/mL solution

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

CYRAMZA® (ramucirumab): Approval for Treatment of HCC

Cyramza (ramucirumab), as a single agent, is indicated for the treatment of HCC who have an AFP ≥400 ng/mL and have been treated with sorafenib.

Detailed Information

On May 10, 2019, the FDA approved ramucirumab as a single agent for the treatment of patients with HCC who have an AFP ≥400 ng/mL and have been treated with sorafenib therapy.1

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly


1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


AFP = alpha-fetoprotein

FDA = Food and Drug Administration 

HCC = hepatocellular carcinoma

Date of Last Review: March 28, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical